Clinical Trials Browser

durvalumab × Genitourinary × 30 days × Clear all

NCT04628767 2026-04-17

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03795207 2026-03-31

POSTCARD

Phase 2 Active not recruiting

Node; Prostate

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Carcinoma, Transitional Cell